InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx

“We are delighted to welcome Gabriela to our team. She brings deep clinical development expertise in immune-inflammatory diseases, a strong record of registrational and regulatory success, and hands-on experience leading global programs and teams. Her background in renal and complement-driven diseases is highly complementary to our efforts, and her leadership will be invaluable as we advance izicopan into its next phase of development and continue to build long-term value across our pipeline.”

Gabriela Alperovich, Senior Vice President & Global Head of Clinical Development at InflaRx

“I am excited to join InflaRx at such a pivotal moment for the Company and its complement-targeted platform. Throughout my career, I have focused on immune-inflammatory diseases, including renal diseases such as IgA nephropathy, lupus nephritis, or ANCA-associated vasculitis, where modulating the complement system can be truly disease-modifying for patients. InflaRx's differentiated approach to C5a and C5aR inhibition, together with the best-in-class potential emerging for izicopan, represents a compelling opportunity to bring meaningful new therapies to patients with high unmet need. I look forward to working with the dedicated team at InflaRx to advance these programs.”